TherapeuticsMD
TXMD
138 hedge funds and large institutions have $1.18B invested in TherapeuticsMD in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 49 increasing their positions, 48 reducing their positions, and 15 closing their positions.
100% more call options, than puts
Call options by funds: $3.38M | Put options by funds: $1.69M
24% more capital invested
Capital invested by funds: $948M → $1.18B (+$232M)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
2% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 48
0.01% less ownership
Funds ownership: 1.67% → 1.66% (-0.01%)
5% less funds holding
Funds holding: 146 → 138 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$68M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$13.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.8M |
| 4 |
NM
Newtyn Management
New York
|
+$8.36M |
| 5 |
CCI
Columbus Circle Investors
|
+$8.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.4M |
| 2 |
Millennium Management
New York
|
-$10.9M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$5.3M |
| 4 |
Bank of New York Mellon
New York
|
-$4.92M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$3.35M |
TXMD Hedge Fund Activity: Q1 2017 in Review
138 of the 4,033 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2017, worth a combined $1.18B — up 24% from $948M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TXMD positions and 15 closed out — a net gain of 1 holder — while 49 added to existing stakes and 48 trimmed.
The largest buyer was BlackRock, adding an estimated $68M. The largest seller was Wellington Management Group, exiting entirely with an estimated $33.4M sold.
- 138 institutional investors held TherapeuticsMD (TXMD) as of Q1 2017, down from 146 in Q4 2016.
- Funds reported $1.18B of TherapeuticsMD stock for Q1 2017, up 24% quarter-over-quarter.
- 16 funds opened new TherapeuticsMD positions in Q1 2017 and 15 closed out, a net change of +1 holder.
- The largest TherapeuticsMD buyer in Q1 2017 was BlackRock, an estimated $68M added.
- The largest TherapeuticsMD seller in Q1 2017 was Wellington Management Group, an estimated $33.4M sold.
Based on aggregated 13F filings for Q1 2017.